CHP
MYGN icon

Cable Hill Partners’s Myriad Genetics MYGN Stock Holding History

Cable Hill Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-476
Closed -$17K – 991
2017
Q3 		$17K Hold
476
– – 0.01% 441
2017
Q2 		$12K Hold
476
– – 0.01% 361
2017
Q1 		$9K Hold
476
– – ﹤0.01% 416
2016
Q4 		$8K Hold
476
– – ﹤0.01% 453
2016
Q3 		$10K Buy
+476
New +$12.1K 0.01% 430
2015
Q2 		– Sell
-640
Closed -$22K – 743
2015
Q1 		$22K Hold
640
– – 0.02% 265
2014
Q4 		$22K Buy
+640
New +$22.7K 0.02% 275

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cable Hill Partners's MYGN Position: Q4 2017 in Review

Cable Hill Partners sold out of Myriad Genetics (MYGN) in Q4 2017, closing a stake of 476 shares — an estimated $17K sold.

Cable Hill Partners first reported a position in MYGN in Q4 2014 and held it in 7 quarters. The position peaked at $22K in Q1 2015. 250 funds tracked by Wall St. Rank hold MYGN as of Q4 2017.

  • Cable Hill Partners reported no remaining Myriad Genetics position as of Q4 2017 after selling out during the quarter.
  • Cable Hill Partners sold 476 Myriad Genetics shares in Q4 2017, an estimated $17K.
  • Cable Hill Partners first reported a position in Myriad Genetics in Q4 2014 and held it in 7 quarters.
  • Cable Hill Partners's Myriad Genetics position peaked at $22K in Q1 2015.
  • 250 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2017.

Based on Cable Hill Partners's 13F filing for Q4 2017, filed 22 Feb 2018.